Eone Diagnomics Genome Center Co., Ltd.

KOSDAQ:A245620 Stock Report

Market Cap: ₩57.4b

Eone Diagnomics Genome Center Past Earnings Performance

Past criteria checks 0/6

Eone Diagnomics Genome Center's earnings have been declining at an average annual rate of -35.4%, while the Life Sciences industry saw earnings growing at 22.4% annually. Revenues have been growing at an average rate of 12% per year.

Key information

-35.4%

Earnings growth rate

-31.4%

EPS growth rate

Life Sciences Industry Growth53.7%
Revenue growth rate12.0%
Return on equity-55.1%
Net Margin-53.9%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

There's No Escaping Eone Diagnomics Genome Center Co., Ltd.'s (KOSDAQ:245620) Muted Revenues Despite A 43% Share Price Rise

Feb 29
There's No Escaping Eone Diagnomics Genome Center Co., Ltd.'s (KOSDAQ:245620) Muted Revenues Despite A 43% Share Price Rise

Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?

Apr 06
Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?

If You Had Bought Eone Diagnomics Genome Center (KOSDAQ:245620) Shares A Year Ago You'd Have Earned 54% Returns

Feb 24
If You Had Bought Eone Diagnomics Genome Center (KOSDAQ:245620) Shares A Year Ago You'd Have Earned 54% Returns

Do Insiders Own Lots Of Shares In Eone Diagnomics Genome Center Co., Ltd. (KOSDAQ:245620)?

Jan 20
Do Insiders Own Lots Of Shares In Eone Diagnomics Genome Center Co., Ltd. (KOSDAQ:245620)?

Eone Diagnomics Genome Center (KOSDAQ:245620) Is Carrying A Fair Bit Of Debt

Dec 16
Eone Diagnomics Genome Center (KOSDAQ:245620) Is Carrying A Fair Bit Of Debt

Revenue & Expenses Breakdown

How Eone Diagnomics Genome Center makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A245620 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2473,966-39,88413,8252,575
31 Dec 2388,457-33,02713,2162,702
30 Sep 23100,554-30,79113,1572,674
30 Jun 2399,636-37,70513,9813,300
31 Mar 2396,173-24,10213,9083,256
31 Dec 2294,244-29,86514,7724,509
30 Sep 2291,964-39,72817,2015,241
30 Jun 2295,540-30,07517,5425,211
31 Mar 2290,842-22,79617,9315,083
31 Dec 2189,282-20,66717,5264,371
30 Sep 2191,354-9,23816,1646,334
30 Jun 2195,302-6,55618,6185,684
31 Mar 2199,049-11,57020,5183,970
31 Dec 2092,541-10,39820,2793,614
30 Sep 2080,840-4,39919,9741,118
30 Jun 2065,727-10,71314,8691,242
31 Mar 2059,647-10,51811,2742,079
31 Dec 1956,722-9,80210,5671,667
30 Sep 1955,273-8,76510,9101,771
30 Jun 1946,550-8,5009,9761,908
31 Mar 1930,772-8,2078,6121,957
31 Dec 1821,497-7,6027,1111,855
30 Sep 188,953-7,1135,9001,984
30 Jun 185,183-5,9484,6871,914
31 Mar 184,827-5,6924,702970
31 Dec 173,235-6,2864,3851,500
31 Dec 161,393-3,8672,2781,128

Quality Earnings: A245620 is currently unprofitable.

Growing Profit Margin: A245620 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A245620 is unprofitable, and losses have increased over the past 5 years at a rate of 35.4% per year.

Accelerating Growth: Unable to compare A245620's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A245620 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.9%).

Return on Equity

High ROE: A245620 has a negative Return on Equity (-55.11%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/03 12:38
End of Day Share Price 2024/04/05 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eone Diagnomics Genome Center Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tal Mi LeeSK Securities Co., Ltd.